Holderness Investments Co. Purchases 300 Shares of Becton, Dickinson and Company (NYSE:BDX)

Holderness Investments Co. increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 27.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,397 shares of the medical instruments supplier’s stock after purchasing an additional 300 shares during the period. Holderness Investments Co.’s holdings in Becton, Dickinson and Company were worth $326,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Jennison Associates LLC grew its holdings in shares of Becton, Dickinson and Company by 4.9% during the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after purchasing an additional 18,786 shares during the last quarter. Norden Group LLC grew its position in shares of Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after acquiring an additional 49,559 shares during the period. Franklin Street Advisors Inc. NC purchased a new stake in Becton, Dickinson and Company in the first quarter worth $11,998,000. Avity Investment Management Inc. increased its stake in shares of Becton, Dickinson and Company by 3.5% in the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock worth $40,257,000 after purchasing an additional 5,527 shares in the last quarter. Finally, Caden Capital Partners LP grew its position in shares of Becton, Dickinson and Company by 26.7% during the 4th quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock valued at $20,340,000 after purchasing an additional 17,599 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $233.50 on Monday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $269.52. The stock’s 50-day simple moving average is $235.51 and its 200-day simple moving average is $235.54. The company has a market capitalization of $67.48 billion, a price-to-earnings ratio of 51.43, a PEG ratio of 1.91 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter in the prior year, the firm earned $2.96 EPS. The business’s revenue was up 2.3% on a year-over-year basis. As a group, analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.63%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Raymond James lowered their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Stifel Nicolaus increased their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup lowered their target price on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Evercore ISI cut their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $279.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.